PDF(Sci-hub)
Abstract：
BACKGROUND: Interest is growing in the role of pituitary adenylate cyclase-activating polypeptide (PACAP) and its specific PAC1 receptor in migraine and in their antagonism as a strategy for migraine prevention.
UNASSIGNED: We discuss and critically evaluate (i) the evidence of the role of PACAP in migraine pathophysiology and (ii) the first clinical trials in migraine prophylaxis with monoclonal antibodies AMG 301 and ALD1910 which act against PAC1 and PACAP38 respectively. We examined PubMed, Scopus, and ClinicalTrials.gov electronic databases to examine the relevant material.
UNASSIGNED: There is much proof of the ability of PACAP to cause migraine, but there is limited evidence that blocking PACAP or PAC1 receptor can prevent migraine. However, the potential of anti-PACAP antibodies in migraine prophylaxis is high. Theoretically, if these antibodies block the activation of the trigeminovascular system, they will prevent the onset of migraine attacks. There are still knowledge gaps in the role of PACAP in migraine and the risk/benefit ratio of anti-PACAP antibodies must be carefully studied.
UNASSIGNED: We discuss and critically evaluate (i) the evidence of the role of PACAP in migraine pathophysiology and (ii) the first clinical trials in migraine prophylaxis with monoclonal antibodies AMG 301 and ALD1910 which act against PAC1 and PACAP38 respectively. We examined PubMed, Scopus, and ClinicalTrials.gov electronic databases to examine the relevant material.
UNASSIGNED: There is much proof of the ability of PACAP to cause migraine, but there is limited evidence that blocking PACAP or PAC1 receptor can prevent migraine. However, the potential of anti-PACAP antibodies in migraine prophylaxis is high. Theoretically, if these antibodies block the activation of the trigeminovascular system, they will prevent the onset of migraine attacks. There are still knowledge gaps in the role of PACAP in migraine and the risk/benefit ratio of anti-PACAP antibodies must be carefully studied.
摘要：
背景：人们对垂体腺苷酸环化酶激活多肽（PACAP）及其特异性PAC1受体在偏头痛中的作用及其作为偏头痛预防策略的拮抗作用越来越感兴趣。
■我们讨论并严格评估（i）PACAP在偏头痛病理生理学中的作用的证据，以及（ii）使用单克隆抗体AMG301和ALD1910预防偏头痛的首次临床试验，分别针对PAC1和PACAP38。我们检查了PubMed,Scopus,和ClinicalTrials.gov电子数据库来检查相关材料。
■有很多证据证明PACAP能够引起偏头痛，但阻断PACAP或PAC1受体可预防偏头痛的证据有限.然而,抗PACAP抗体在偏头痛预防中的潜力很高.理论上,如果这些抗体阻断三叉神经血管系统的激活，它们将防止偏头痛发作。PACAP在偏头痛中的作用仍然存在知识空白，必须仔细研究抗PACAP抗体的风险/收益比。
■我们讨论并严格评估（i）PACAP在偏头痛病理生理学中的作用的证据，以及（ii）使用单克隆抗体AMG301和ALD1910预防偏头痛的首次临床试验，分别针对PAC1和PACAP38。我们检查了PubMed,Scopus,和ClinicalTrials.gov电子数据库来检查相关材料。
■有很多证据证明PACAP能够引起偏头痛，但阻断PACAP或PAC1受体可预防偏头痛的证据有限.然而,抗PACAP抗体在偏头痛预防中的潜力很高.理论上,如果这些抗体阻断三叉神经血管系统的激活，它们将防止偏头痛发作。PACAP在偏头痛中的作用仍然存在知识空白，必须仔细研究抗PACAP抗体的风险/收益比。
